Brind.
  1. The FDA is reviewing drug data and company resubmissions, while also overseeing the functions of the U.S. Department of Health and Human Services.
  2. FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.

Karl Deisseroth is confirmed as a co-founder and advisory board member of MapLight.

1 report, 1 independent Updated 00:00
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Karl Deisseroth is confirmed as a co-founder and advisory board member of MapLight.

Who's involved

What this event is mainly about
MapLightKarl Deisseroth

Keep exploring

Part of

FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks. All 1 developments

Within The FDA is reviewing drug data and company resubmissions, while also overseeing the functions of the U.S. Department of Health and Human Services.

The entities involved

Coverage

Newest first; wire copies grouped